Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.35 |
| ▸ | BRAF | P15056 | 3/20 | 0.35 |
| ▸ | AURKA | O14965 | 5/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4299118 | 0.88 | DHODH (0.50) | DHODHJAK2JAK3PIK3C3NTRK1 | |
| SCHEMBL13663573 | 0.86 | JAK2 (0.43) | DHODHJAK2JAK3BRAFAURKA | |
| SCHEMBL13663512 | 0.84 | JAK2 (0.42) | DHODHJAK2JAK3PIK3C3BRAF | |
| SCHEMBL13769289 | 0.82 | DHODH (0.53) | DHODHJAK2JAK3PIK3C3NTRK1 | |
| SCHEMBL13663502 | 0.80 | DHODH (0.53) | DHODHJAK2JAK3PIK3C3AURKA | |
| SCHEMBL4166700 | 0.79 | DHODH (0.46) | DHODHJAK2JAK3PIK3C3BRAF | |
| SCHEMBL13663556 | 0.78 | DHODH (0.80) | DHODHJAK2JAK3PIK3C3NTRK1 | |
| SCHEMBL4302253 | 0.78 | DHODH (0.37) | DHODHJAK2JAK3PIK3C3TRPA1 | |
| SCHEMBL4170907 | 0.75 | JAK2 (0.45) | DHODHJAK2JAK3AURKAAURKB | |
| SCHEMBL4174651 | 0.74 | JAK2 (0.41) | DHODHJAK2JAK3BRAFAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | MAP3K1, MAP3K15, MAP3K5 | DHODH 3096/4885JAK2 39/4885JAK3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.